KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy

被引:10
|
作者
Lunger, Lukas [1 ]
Retz, Margitta [1 ]
Bandur, Miriam [1 ]
Souchay, Marc [1 ]
Vitzthum, Elisabeth [1 ]
Jaeger, Marion [1 ]
Weirich, Gregor [2 ]
Schuster, Tibor [3 ]
Autenrieth, Michael [1 ]
Kuebler, Hubert [1 ,4 ]
Maurer, Tobias [1 ,5 ,6 ]
Thalgott, Mark [1 ]
Herkommer, Kathleen [1 ]
Koll, Florestan [1 ]
Gschwend, Juergen E. [1 ]
Nawroth, Roman [1 ]
Heck, Matthias M. [1 ]
机构
[1] Tech Univ Munich, Rechts Isar Med Ctr, Dept Urol, Munich, Germany
[2] Tech Univ Munich, Rechts Isar Med Ctr, Dept Pathol & Pathol Anat, Munich, Germany
[3] McGill Univ, Dept Family Med, Montreal, PQ, Canada
[4] Univ Wurzburg, Dept Urol, Wurzburg, Germany
[5] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[6] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
关键词
METASTASES; SURVIVAL; IMPACT; MICROMETASTASES; THERAPY; MARKER; PCR;
D O I
10.1038/s41391-020-00283-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Lymph-node (LN) metastasis in prostate cancer (PC) is a main risk factor for tumor recurrence after radical prostatectomy (RP). Molecular analysis facilitates detection of small-volume LN metastases with higher sensitivity than histopathology. We aimed to prospectively evaluate six candidate gene markers for detection of pelvic LN metastases and to determine their ability to predict biochemical recurrence-free survival (bRFS) in patients treated with RP. Methods The expression of kallikrein 2, 3, and 4 (KLK2, KLK3, and KLK4), prostate-specific membrane antigen (PSMA), transmembrane serine protease 2 (TMPRSS2) and transient receptor potential cation channel subfamily M member 8 (TRPM8) was assessed using qPCR. We analyzed LNs from 111 patients (intermediate PC,n = 32 (29%); high-risk PC,n = 79 (71%)) who underwent RP and extended pelvic lymph-node dissection without neoadjuvant treatment. Results Overall, 2411 LNs were examined by molecular and histopathologic examination. Histopathology detected 69 LN metastases in 28 (25%) patients. KLK2 and KLK3 diagnostically performed best and classified all pN1-patients correctly as molecular node-positive (molN1/pN1). The concordance on LN level was best for KLK3 (96%). KLK2, KLK3, KLK4, PSMA, TMPRSS2, and TRPM8 reclassified 27 (24%), 32 (29%), 29 (26%), 8 (7%), 13 (12%), and 23 (21%) pN0-patients, respectively, as node-positive (pN0/molN1). On multivariable cox regression analysis molecular LN status (molN1 vs. molN0) using KLK3 (HR 4.0,p = 0.04) and TMPRSS2 (HR 5.1,p = 0.02) were independent predictors of bRFS. Median bRFS was shorter in patients with only molecular positive LNs (molN1/pN0) for KLK3 (24 months,p = 0.001) and for TMPRSS2 (12 months,p < 0.001) compared to patients with negative nodes (molN0/pN0) (median bRFS not reached). Conclusions For diagnostic purposes, KLK3 showed highest concordance with histopathology for detection of LN metastases in PC patients undergoing RP. For prognostic purposes, KLK3 and TMPRSS2 expression were superior to histopathologic LN status and other transcripts tested for molecular LN status. We suggest a combined KLK3/TMPRSS2 panel as a valuable diagnostic and prognostic tool for molecular LN analysis.
引用
收藏
页码:362 / 369
页数:8
相关论文
共 50 条
  • [1] Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
    Heck, Matthias M.
    Retz, Margitta
    Bandur, Miriam
    Souchay, Marc
    Vitzthum, Elisabeth
    Weirich, Gregor
    Schuster, Tibor
    Autenrieth, Michael
    Kuebler, Hubert
    Maurer, Tobias
    Thalgott, Mark
    Herkommer, Kathleen
    Gschwend, Juergen E.
    Nawroth, Roman
    CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2342 - 2349
  • [2] Molecular lymph node staging for bladder cancer patients undergoing radical cystectomy with pelvic lymph node dissection
    Heck, Matthias M.
    Koll, Florestan J.
    Retz, Margitta
    Autenrieth, Michael
    Magg, Kathrin
    Lunger, Lukas
    Gschwend, Juergen E.
    Nawroth, Roman
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (07) : 639.e11 - 639.e19
  • [3] Decreasing Rate and Extent of Lymph Node Staging in Patients Undergoing Radical Prostatectomy May Undermine the Rate of Diagnosis of Lymph Node Metastases in Prostate Cancer
    Abdollah, Firas
    Sun, Maxine
    Thuret, Rodolphe
    Budaeus, Lars
    Jeldres, Claudio
    Graefen, Markus
    Briganti, Alberto
    Perrotte, Paul
    Rigatti, Patrizio
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    EUROPEAN UROLOGY, 2010, 58 (06) : 882 - 892
  • [4] Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients
    Falkenbach, Fabian
    Kachanov, Mykyta
    Leyh-Bannurah, Sami-Ramzi
    Maurer, Tobias
    Knipper, Sophie
    Koehler, Daniel
    Graefen, Markus
    Sauter, Guido
    Budaeus, Lars
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [5] Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer
    Maxeiner, Andreas
    Grevendieck, Andreas
    Pross, Therese
    Rudl, Marc
    Arnold, Alexander
    Stephan, Carsten
    Jung, Klaus
    Miller, Kurt
    Kilic, Ergin
    Busch, Jonas
    AKTUELLE UROLOGIE, 2019, 50 (06) : 612 - 618
  • [6] Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer
    Engel, Jutta
    Bastian, Patrick J.
    Baur, Helmut
    Beer, Volker
    Chaussy, Christian
    Gschwend, Juergen E.
    Oberneder, Ralph
    Rothenberger, Karl H.
    Stief, Christian G.
    Hoelzel, Dieter
    EUROPEAN UROLOGY, 2010, 57 (05) : 754 - 761
  • [7] Topography of Lymph Node Metastases in Prostate Cancer Patients Undergoing Radical Prostatectomy and Extended Lymphadenectomy: Results of a Combined Molecular and Histopathologic Mapping Study
    Heck, Matthias M.
    Retz, Margitta
    Bandur, Miriam
    Souchay, Marc
    Vitzthum, Elisabeth
    Weirich, Gregor
    Mollenhauer, Martin
    Schuster, Tibor
    Autenrieth, Michael
    Kuebler, Hubert
    Maurer, Tobias
    Thalgott, Mark
    Herkommer, Kathleen
    Gschwend, Juergen E.
    Nawroth, Roman
    EUROPEAN UROLOGY, 2014, 66 (02) : 222 - 229
  • [8] Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
    Kim, Dowook
    Kim, Dong-Yun
    Kim, Jae-Sung
    Hong, Sung Kyu
    Byun, Seok-Soo
    Lee, Sang Eun
    PLOS ONE, 2021, 16 (09):
  • [9] Molecular lymph node staging in prostate and bladder cancer
    Heck, M. M.
    Retz, M.
    Nawroth, R.
    UROLOGE, 2014, 53 (04): : 484 - +
  • [10] Molecular lymph node staging in prostate and bladder cancer
    Heck, M. M.
    Retz, M.
    Nawroth, R.
    UROLOGE, 2014, 53 (04): : 484 - +